Genentech inks $650M deal with protein degradation pioneer Arvinas
Genentech is doubling down on its commitment to New Haven biotech Arvinas, extending the duo’s partnership and tacking an additional $350 million onto the total …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.